Global Anti-angiogenic Ophthalmic Agent Market Growth 2023-2029

Global Anti-angiogenic Ophthalmic Agent Market Growth 2023-2029

The global Anti-angiogenic Ophthalmic Agent market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Anti-angiogenic Ophthalmic Agent is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Anti-angiogenic Ophthalmic Agent is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Anti-angiogenic Ophthalmic Agent is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Anti-angiogenic Ophthalmic Agent players cover Gilead Sciences, Inc., Eyetech Inc., Becton, Dickinson and Company, Regeneron Pharmaceuticals, Inc., Genentech, Inc., Novartis AG, Allergan plc, Bayer AG and Santen Pharmaceutical Co., Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Anti-angiogenic ophthalmic agents act as antagonists against the vascular endothelial growth factor (VEGF). When retinal pigment cells become ischemic and dry up VEGF stimulates generation of new blood vessels by a process called neovascularization. If new blood vessels are not generated properly, leakage occurs in retina, which leads to vision loss. Angiogenesis plays an important role in chronic inflammation and fibrosis, tumor growth and vascularization of ischemic tissue.

LPI (LP Information)' newest research report, the “Anti-angiogenic Ophthalmic Agent Industry Forecast” looks at past sales and reviews total world Anti-angiogenic Ophthalmic Agent sales in 2022, providing a comprehensive analysis by region and market sector of projected Anti-angiogenic Ophthalmic Agent sales for 2023 through 2029. With Anti-angiogenic Ophthalmic Agent sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-angiogenic Ophthalmic Agent industry.

This Insight Report provides a comprehensive analysis of the global Anti-angiogenic Ophthalmic Agent landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-angiogenic Ophthalmic Agent portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Anti-angiogenic Ophthalmic Agent market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-angiogenic Ophthalmic Agent and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-angiogenic Ophthalmic Agent.

This report presents a comprehensive overview, market shares, and growth opportunities of Anti-angiogenic Ophthalmic Agent market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Myopic Choroidal Neovascularization
Macular Edema
Diabetic Retinopathy
Macular Degeneration

Segmentation by application
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Gilead Sciences, Inc.
Eyetech Inc.
Becton, Dickinson and Company
Regeneron Pharmaceuticals, Inc.
Genentech, Inc.
Novartis AG
Allergan plc
Bayer AG
Santen Pharmaceutical Co., Ltd.
Shanghai Pharmaceuticals
Johnson & Johnson
Pfizer
Sun Pharma
Otsuka Pharmaceutical Co. Ltd
Daiichi Sankyo
ERC Labs
Medicom Health care
Implant ophthalmic products GmbH
The Geuder Group, MORCHER GmbH
Novamedika

Key Questions Addressed in this Report

What is the 10-year outlook for the global Anti-angiogenic Ophthalmic Agent market?

What factors are driving Anti-angiogenic Ophthalmic Agent market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Anti-angiogenic Ophthalmic Agent market opportunities vary by end market size?

How does Anti-angiogenic Ophthalmic Agent break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.